[HTML][HTML] Applications of single-cell RNA sequencing in drug discovery and development

B Van de Sande, JS Lee, E Mutasa-Gottgens… - Nature Reviews Drug …, 2023 - nature.com
Single-cell technologies, particularly single-cell RNA sequencing (scRNA-seq) methods,
together with associated computational tools and the growing availability of public data …

Algorithms to estimate Shapley value feature attributions

H Chen, IC Covert, SM Lundberg, SI Lee - Nature Machine Intelligence, 2023 - nature.com
Feature attributions based on the Shapley value are popular for explaining machine
learning models. However, their estimation is complex from both theoretical and …

A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia

AGX Zeng, S Bansal, L Jin, A Mitchell, WC Chen… - Nature medicine, 2022 - nature.com
The treatment landscape of acute myeloid leukemia (AML) is evolving, with promising
therapies entering clinical translation, yet patient responses remain heterogeneous, and …

[HTML][HTML] Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution

A Rodriguez-Meira, R Norfo, S Wen, AL Chédeville… - Nature …, 2023 - nature.com
Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-
mutation-driven clonal evolution and subsequent transformation is a crucial step toward the …

An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia

A Lasry, B Nadorp, M Fornerod, D Nicolet, H Wu… - Nature cancer, 2023 - nature.com
Acute myeloid leukemia (AML) is a hematopoietic malignancy with poor prognosis and
limited treatment options. Here we provide a comprehensive census of the bone marrow …

A compendium of mutational cancer driver genes

F Martínez-Jiménez, F Muiños, I Sentís… - Nature Reviews …, 2020 - nature.com
A fundamental goal in cancer research is to understand the mechanisms of cell
transformation. This is key to developing more efficient cancer detection methods and …

[HTML][HTML] Integrative analysis of drug response and clinical outcome in acute myeloid leukemia

D Bottomly, N Long, AR Schultz, SE Kurtz, CE Tognon… - Cancer cell, 2022 - cell.com
Acute myeloid leukemia (AML) is a cancer of myeloid-lineage cells with limited therapeutic
options. We previously combined ex vivo drug sensitivity with genomic, transcriptomic, and …

[HTML][HTML] Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients

AC Aschenbrenner, M Mouktaroudi, B Krämer… - Genome medicine, 2021 - Springer
Abstract Background The SARS-CoV-2 pandemic is currently leading to increasing numbers
of COVID-19 patients all over the world. Clinical presentations range from asymptomatic …

Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia

S Pei, DA Pollyea, A Gustafson, BM Stevens… - Cancer discovery, 2020 - AACR
Venetoclax-based therapy can induce responses in approximately 70% of older previously
untreated patients with acute myeloid leukemia (AML). However, up-front resistance as well …

Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease

CS Hourigan, LW Dillon, G Gui, BR Logan… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Patients with acute myeloid leukemia (AML) in remission remain at risk for
relapse even after allogeneic hematopoietic cell transplantation (alloHCT). AML measurable …